Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Weight-loss jabs such as Ozempic are being hailed as a potential breakthrough in the fight against obesity. Demand, fuelled ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Embarking on the quest to lose weight can be a risky business. Yo-yo dieting, compulsive binging, muscle wasting and brain ...

Wonder drugs’ like Ozempic, hailed by celebrities and some medics as a cure for an ever-mounting list of conditions, most notably obesity and diabetes, have started to appear in darker headlines ...

These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...